Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Cash from Financing Activities (2019 - 2024)

Bioadaptives' Cash from Financing Activities history spans 6 years, with the latest figure at $194115.0 for Q4 2024.

  • For Q4 2024, Cash from Financing Activities changed N/A year-over-year to $194115.0; the TTM value through Sep 2025 reached $294115.0, down 18.11%, while the annual FY2024 figure was $326211.0, 25.88% up from the prior year.
  • Cash from Financing Activities for Q4 2024 was $194115.0 at Bioadaptives, up from $100000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $194115.0 in Q4 2024 and bottomed at $12582.0 in Q2 2020.
  • The 5-year median for Cash from Financing Activities is $52000.0 (2021), against an average of $70610.0.
  • The largest annual shift saw Cash from Financing Activities surged 496.09% in 2021 before it plummeted 57.49% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $44931.0 in 2020, then rose by 15.73% to $52000.0 in 2021, then plummeted by 35.81% to $33377.0 in 2022, then skyrocketed by 403.64% to $168100.0 in 2023, then rose by 15.48% to $194115.0 in 2024.
  • Per Business Quant, the three most recent readings for BDPT's Cash from Financing Activities are $194115.0 (Q4 2024), $100000.0 (Q3 2024), and $168100.0 (Q3 2023).